Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adults 50 Years and Older
NCT06744205Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jan 2025
- Primary completion
- May 2026
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in influenza (11 arms), sponsored by Sanofi. Primary endpoints: Number of participants with immediate unsolicited systemic adverse events at 30 minutes, Number of participants with solicited injection site reactions at 7 days and 15 more. Started Jan 2025; status: completed.
02
Conditions
influenza
Beyond the preview
Go deeper on NCT06744205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06744205.